Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy with a $20 price target, highlighting the company’s focus on oncology asset TPI-287 for recurrent glioblastoma. Maxim also notes CNS Pharma’s roadmap for TPI-287 and potential path forward with Berubicin, positioning the stock for recovery with cash runway into the second half of 2026.

For powerful investing tools and expert analyst insights, take advantage of TipRanks Premium at 50% off! Unlock advanced data to invest with confidence. Published first on TheFly, the ultimate source for real-time, market-moving financial news. Try it now for the latest updates.

Check out today’s best-performing stocks on TipRanks to stay informed on market trends and opportunities. Read more on CNSP for detailed analysis and insights. For disclaimer and disclosure information, visit the provided links to ensure transparency and accuracy in reporting.

Read more at Yahoo Finance: CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap